Online, October 17, 2015 (Newswire.com) - Ee Thye Yin, PhD, a world leading expert in the field of clotting and coagulation assays , owner and chief scientist for Heptest Laboratories has made it his life work to innovate and create the highest quality coagulation products on the market. Dr. Yin says, “I have seen what Lee Biosolutions is capable of doing and I am looking forward to seeing our products being used around the world each and every day.”
Future POC (Point of Care ) products for Lee Biosolutions will include the Heptest POC-Hi which accurately and specifically measures high levels of unfractionated heparin in citrated whole blood during cardiopulmonary(open heart) bypass surgery (CPB), Heptest POC-Lo which accurately measures low levels of active heparin, low molecular weight heparin or direct inhibitors, allowing full monitoring during low dose heparin therapy, Heptest POC Dia (HPD) that will be used to monitor low molecular weight heparin during kidney dialysis, Heptest PF4 (platelet Factor 4) which is to be used for rapid diagnosis of inflammation and prothrombotic state and Heptest POC NOAC’s ( new oral anticoagulants) to monitor patients on the new oral anticoagulants. Lee Biosolutions will also have the technology to produce Normal Human Plasma, Normal Control Plasma, Abnormal Control Plasma, Rabbit Brain Cephalin, bovine Plasma Prothrombin –complex concentrate, Bovine Factor XA(RVV-activated) Concentrate.
About Lee Biosolutions, Inc. We are headquartered in a 41,000 square feet state of the art cGMP-compliant facility in Maryland Heights, MO. Lee Biosolutions is a certified, licensed ISO, FDA, EPA and USDA leader in process development and bulk manufacturing of high quality purified enzymes and related proteins for research and clinical diagnostic tests. Lee Biosolutions products are used for such pathologies as cardiac disease, cancer, diabetes, urine analysis, coagulation, obesity, inflammatory, neurological, autoimmune diseases and immunological disorders
Source URL: http://prweb.com/releases/2015/10/prweb13027641.htm
Share: